SCHEMBL30510341

SCHEMBL30510341

COC(=O)N(C1c2ccccc2-c2ccccc21)[C@@H](CCc1ccc(Cl)c(Cl)c1)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.38
▸ CHRM5 P08912 3/20 0.37
▸ CHRM1 P11229 3/20 0.37
▸ CHRM3 P20309 3/20 0.37
▸ LIPG Q9Y5X9 3/20 0.36
▸ CHRM2 P08172 2/20 0.36
▸ PLAAT3 P53816 1/20 0.36
▸ PLAAT5 Q96KN8 1/20 0.36
▸ PLAAT2 Q9NWW9 1/20 0.36
▸ PLAAT4 Q9UL19 1/20 0.36
▸ CDK8 P49336 1/20 0.36
▸ CLK4 Q9HAZ1 1/20 0.36
▸ PAX8 Q06710 1/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ RECQL P46063 1/20 0.36
▸ BLM P54132 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ PDPK1 O15530 1/20 0.35
▸ TRPV1 Q8NER1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25186430 1.00 TSHR (0.38) TSHRCHRM5CHRM1CHRM3LIPG
SCHEMBL25182303 0.89 MMP7 (0.36) MEN1KMT2APPARGPPARA
SCHEMBL30510243 0.89 MMP7 (0.36) MEN1KMT2APPARGPPARA
SCHEMBL30510294 0.89 PPARG (0.41) MEN1KMT2APPARGPPARA
SCHEMBL25178770 0.89 PPARG (0.41) MEN1KMT2APPARGPPARA
SCHEMBL25178771 0.88 ALDH1A1 (0.39) PLAAT3PLAAT5PLAAT2PLAAT4MEN1
SCHEMBL30510266 0.88 ALDH1A1 (0.39) PLAAT3PLAAT5PLAAT2PLAAT4MEN1
SCHEMBL25173040 0.87 PRSS1 (0.39) TSHRMEN1KMT2A
SCHEMBL25178739 0.85 FFAR1 (0.36) PLAAT3PLAAT5PLAAT2PLAAT4MEN1
SCHEMBL25185680 0.84 KMT2A (0.40) CHRM5CHRM1CHRM3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-07-29 — — US disclosed
US-20240400617-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-12-05 — — US disclosed
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS TSHR 3295/4885CHRM5 4884/4885CHRM1 4827/4885
US-20240400617-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS TSHR 3295/4885CHRM5 4884/4885CHRM1 4827/4885
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action KRAS, NRAS, HRAS TSHR 3295/4885CHRM5 4884/4885CHRM1 4827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback